Completed PHASE3 INTERVENTIONAL 2-arm NCT01949935

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting (MIR-CABG)

MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting

Sponsor: Horizon Health Network

Conditions Surgical Site Infections

Interventions Mupirocin

Updated 5 times since 2017 Last updated: Sep 20, 2013 Started: Mar 31, 2009 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Surgical Site Infections, this trial is completed. The trial is conducted by Horizon Health Network and has accumulated 5 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Horizon Health Network

Data source: Horizon Health Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint John, Canada